{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T17:23:25Z","timestamp":1791912205450,"version":"4.3.4"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["24ek0109714h0001"],"award-info":[{"award-number":["24ek0109714h0001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["24mk0121292h0001"],"award-info":[{"award-number":["24mk0121292h0001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP18H04047"],"award-info":[{"award-number":["JP18H04047"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["23K15264"],"award-info":[{"award-number":["23K15264"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-63744-0","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T16:53:55Z","timestamp":1759251235000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Inhibition of formyl peptide receptor-1-mediated cell death as a therapy for lethal cutaneous drug reactions in preclinical models"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5389-3442","authenticated-orcid":false,"given":"Haruna","family":"Kimura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7606-5551","authenticated-orcid":false,"given":"Akito","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoki","family":"Nishiguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong Ha","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9898-3200","authenticated-orcid":false,"given":"Masatoshi","family":"Eguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0485-9803","authenticated-orcid":false,"given":"Manao","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youichi","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3198-4853","authenticated-orcid":false,"given":"Takeaki","family":"Ozawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7582-8609","authenticated-orcid":false,"given":"Riichiro","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"key":"63744_CR1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1093\/bjd\/ljae321","volume":"92","author":"N Hama","year":"2024","unstructured":"Hama, N. et al. Recent progress in Stevens-Johnson syndrome\/toxic epidermal necrolysis: diagnostic criteria, pathogenesis and treatment. Br. J. Dermatol. 92, 9\u201318 (2024).","journal-title":"Br. J. Dermatol."},{"key":"63744_CR2","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1007\/s40123-023-00725-w","volume":"12","author":"G T\u00f3th","year":"2023","unstructured":"T\u00f3th, G. et al. Ophthalmic aspects of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Narrative Review. Ophthalmol. Ther. 12, 1795\u20131811 (2023).","journal-title":"Ophthalmol. Ther."},{"key":"63744_CR3","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1001\/jamadermatol.2016.5668","volume":"153","author":"S Zimmermann","year":"2017","unstructured":"Zimmermann, S. et al. SystemiC Immunomodulating Therapies For Stevens-johnson Syndrome And Toxic Epidermal Necrolysis: A Systematic Review And Meta-analysis. JAMA Dermatol. 153, 514\u2013522 (2017).","journal-title":"JAMA Dermatol."},{"key":"63744_CR4","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1111\/j.1365-2133.2012.10965.x","volume":"167","author":"YC Huang","year":"2012","unstructured":"Huang, Y. C., Li, Y. C. & Chen, T. J. The efficacy of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis: a systematic review and meta-analysis. Br. J. Dermatol. 167, 424\u2013432 (2012).","journal-title":"Br. J. Dermatol."},{"key":"63744_CR5","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/ijd.12423","volume":"54","author":"SJ Barron","year":"2015","unstructured":"Barron, S. J., Del Vecchio, M. T. & Aronoff, S. C. Intravenous immunoglobulin in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis: a meta-analysis with meta-regression of observational studies. Int J. Dermatol. 54, 108\u2013115 (2015).","journal-title":"Int J. Dermatol."},{"key":"63744_CR6","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.jaad.2018.09.063","volume":"85","author":"R Shah","year":"2021","unstructured":"Shah, R., Chen, S. T. & Kroshinsky, D. Use of cyclosporine for the treatment of Stevens-Johnson syndrome\/toxic epidermal necrolysis. J. Am. Acad. Dermatol. 85, 512\u2013513 (2021).","journal-title":"J. Am. Acad. Dermatol."},{"key":"63744_CR7","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1111\/j.1346-8138.2010.01154.x","volume":"38","author":"YM Narita","year":"2011","unstructured":"Narita, Y. M., Hirahara, K., Mizukawa, Y., Kano, Y. & Shiohara, T. Efficacy of plasmapheresis for the treatment of severe toxic epidermal necrolysis: Is cytokine expression analysis useful in predicting its therapeutic efficacy?. J. Dermatol. 38, 236\u2013245 (2011).","journal-title":"J. Dermatol."},{"key":"63744_CR8","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.jdermsci.2020.09.009","volume":"100","author":"Y Sunaga","year":"2020","unstructured":"Sunaga, Y. et al. The nationwide epidemiological survey of Stevens-Johnson syndrome and toxic epidermal necrolysis in Japan, 2016\u22122018. J. Dermatol. Sci. 100, 175\u2013182 (2020).","journal-title":"J. Dermatol. Sci."},{"key":"63744_CR9","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/j.jaip.2022.01.038","volume":"10","author":"J Zhang","year":"2022","unstructured":"Zhang, J. et al. Evaluation of combination therapy with Etanercept and systemic Corticosteroids for Stevens-Johnson Syndrome and toxic epidermal necrolysis: a multicenter observational study. J. Allergy Clin. Immunol. Pr. 10, 1295\u20131304.e6 (2022).","journal-title":"J. Allergy Clin. Immunol. Pr."},{"key":"63744_CR10","doi-asserted-by":"crossref","unstructured":"Wang, C. W., et al. The Taiwan Severe Cutaneous Adverse Reaction (TSCAR) Consortium Randomized, controlled trial of TNF-\u03b1 antagonist in CTL-mediated severe cutaneous adverse reactions. J. Clin. Invest. 128, 985\u2013996 (2018).","DOI":"10.1172\/JCI93349"},{"key":"63744_CR11","doi-asserted-by":"crossref","unstructured":"Hasegawa, A. & Abe, R. Recent advances in managing and understanding Stevens-Johnson syndrome and toxic epidermal necrolysis. F1000Res 9, 612 (2020).","DOI":"10.12688\/f1000research.24748.1"},{"key":"63744_CR12","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1111\/j.1365-2133.1996.tb06976.x","volume":"134","author":"C Paul","year":"1996","unstructured":"Paul, C. et al. Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis. Br. J. Dermatol. 134, 710\u2013714 (1996).","journal-title":"Br. J. Dermatol."},{"key":"63744_CR13","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1126\/science.282.5388.490","volume":"282","author":"I Viard","year":"1998","unstructured":"Viard, I. et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 282, 490\u2013493 (1998).","journal-title":"Science"},{"key":"63744_CR14","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1016\/S0002-9440(10)64284-8","volume":"162","author":"R Abe","year":"2003","unstructured":"Abe, R. et al. Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas ligand. Am. J. Pathol. 162, 1515\u20131520 (2003).","journal-title":"Am. J. Pathol."},{"key":"63744_CR15","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1046\/j.1523-1747.2002.01622.x","volume":"118","author":"A Nassif","year":"2002","unstructured":"Nassif, A. et al. Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis. J. Invest. Dermatol. 118, 728\u2013733 (2002).","journal-title":"J. Invest. Dermatol."},{"key":"63744_CR16","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1016\/j.jaci.2004.07.047","volume":"114","author":"A Nassif","year":"2004","unstructured":"Nassif, A. et al. Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells. J. Allergy Clin. Immunol. 114, 1209\u20131215 (2004).","journal-title":"J. Allergy Clin. Immunol."},{"key":"63744_CR17","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1038\/nm.1884","volume":"14","author":"WH Chung","year":"2008","unstructured":"Chung, W. H. et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat. Med. 14, 1343\u20131350 (2008).","journal-title":"Nat. Med."},{"key":"63744_CR18","doi-asserted-by":"publisher","first-page":"245ra95","DOI":"10.1126\/scitranslmed.3008227","volume":"6","author":"N Saito","year":"2014","unstructured":"Saito, N. et al. An annexin A1-FPR1 interaction contributes to necroptosis of keratinocytes in severe cutaneous adverse drug reactions. Sci. Transl. Med. 6, 245ra95 (2014).","journal-title":"Sci. Transl. Med."},{"key":"63744_CR19","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aax2398","volume":"13","author":"M Kinoshita","year":"2021","unstructured":"Kinoshita, M. et al. Neutrophils initiate and exacerbate Stevens-Johnson syndrome and toxic epidermal necrolysis. Sci. Transl. Med 13, eaax2398 (2021).","journal-title":"Sci. Transl. Med"},{"key":"63744_CR20","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.jaci.2012.09.014","volume":"131","author":"N Saito","year":"2013","unstructured":"Saito, N. et al. Stevens-Johnson syndrome\/toxic epidermal necrolysis mouse model generated by using PBMCs and the skin of patients. J. Allergy Clin. Immunol. 131, 434\u2013441.e1-9 (2013).","journal-title":"J. Allergy Clin. Immunol."},{"key":"63744_CR21","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-024-00514-0","volume":"10","author":"SI Hung","year":"2024","unstructured":"Hung, S. I. et al. Severe cutaneous adverse reactions. Nat. Rev. Dis. Prim. 10, 30 (2024).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"63744_CR22","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nrd1468","volume":"3","author":"T Ashburn","year":"2004","unstructured":"Ashburn, T. & Thor, K. B. Drug repositioning: identifying and developing new uses for existing drugs. Nat. Rev. Drug Discov. 3, 673\u2013683 (2004).","journal-title":"Nat. Rev. Drug Discov."},{"key":"63744_CR23","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1242\/jcs.03338","volume":"120","author":"L Ma","year":"2007","unstructured":"Ma, L. & Pei, G. Beta-arrestin signaling and regulation of transcription. J. Cell Sci. 120, 213\u2013218 (2007).","journal-title":"J. Cell Sci."},{"key":"63744_CR24","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.1021\/ac100104q","volume":"82","author":"N Misawa","year":"2010","unstructured":"Misawa, N. et al. Rapid and high-sensitivity cell-based assays of protein-protein interactions using split click beetle luciferase complementation: an approach to the study of G-protein-coupled receptors. Anal. Chem. 82, 2552\u20132560 (2010).","journal-title":"Anal. Chem."},{"key":"63744_CR25","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1039\/c2mb25443c","volume":"9","author":"M Hattori","year":"2013","unstructured":"Hattori, M. et al. Analysis of temporal patterns of GPCR-\u03b2-arrestin interactions using split luciferase-fragment complementation. Mol. Biosyst. 9, 957\u2013964 (2013).","journal-title":"Mol. Biosyst."},{"key":"63744_CR26","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1021\/cc9800071","volume":"1","author":"AK Ghose","year":"1999","unstructured":"Ghose, A. K., Viswanadhan, V. N. & Wendoloski, J. J. A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases. J. Comb. Chem. 1, 55\u201368 (1999).","journal-title":"J. Comb. Chem."},{"key":"63744_CR27","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1016\/j.jmb.2013.04.011","volume":"425","author":"AM Preininger","year":"2013","unstructured":"Preininger, A. M., Meiler, J. & Hamm, H. E. Conformational flexibility and structural dynamics in GPCR-mediated G protein activation: a perspective. J. Mol. Biol. 425, 2288\u20132298 (2013).","journal-title":"J. Mol. Biol."},{"key":"63744_CR28","doi-asserted-by":"publisher","first-page":"128","DOI":"10.2174\/138161212799040466","volume":"18","author":"C Denis","year":"2012","unstructured":"Denis, C., Sauli\u00e8re, A., Galandrin, S., S\u00e9nard, J. M. & Gal\u00e9s, C. Probing heterotrimeric G protein activation: applications to biased ligands. Curr. Pharm. Des. 18, 128\u2013144 (2012).","journal-title":"Curr. Pharm. Des."},{"key":"63744_CR29","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/ng0592-85","volume":"1","author":"TM Wilkie","year":"1992","unstructured":"Wilkie, T. M. et al. Evolution of the mammalian G protein alpha subunit multigene family. Nat. Genet. 1, 85\u201391 (1992).","journal-title":"Nat. Genet."},{"key":"63744_CR30","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/0165-6147(96)10026-2","volume":"17","author":"G Milligan","year":"1996","unstructured":"Milligan, G., Marshall, F. & Rees, S. G16 as a universal G protein adapter: implications for agonist screening strategies. Trends Pharm. Sci. 17, 235\u2013237 (1996).","journal-title":"Trends Pharm. Sci."},{"key":"63744_CR31","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1177\/108705702237679","volume":"7","author":"DG Witte","year":"2002","unstructured":"Witte, D. G., Cassar, S. C., Masters, J. N., Esbenshade, T. & Hancock, A. A. Use of a fluorescent imaging plate reader-based calcium assay to assess pharmacological differences between the human and rat vanilloid receptor. J. Biomol. Screen 7, 466\u2013475 (2002).","journal-title":"J. Biomol. Screen"},{"key":"63744_CR32","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1111\/j.1745-7254.2008.00775.x","volume":"29","author":"T Zhu","year":"2008","unstructured":"Zhu, T., Fang, L. Y. & Xie, X. Development of a universal high-throughput calcium assay for G-protein- coupled receptors with promiscuous G-protein Galpha15\/16. Acta Pharm. Sin. 29, 507\u2013516 (2008).","journal-title":"Acta Pharm. Sin."},{"key":"63744_CR33","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1007\/s000110050656","volume":"49","author":"X Chen","year":"2000","unstructured":"Chen, X. et al. Characterization of chenodeoxycholic acid as an endogenous antagonist of the G-coupled formyl peptide receptors. Inflamm. Res 49, 744\u2013755 (2000).","journal-title":"Inflamm. Res"},{"key":"63744_CR34","doi-asserted-by":"publisher","first-page":"7050","DOI":"10.4049\/jimmunol.177.10.7050","volume":"177","author":"P Yan","year":"2006","unstructured":"Yan, P. et al. The immunosuppressant cyclosporin A antagonizes human formyl peptide receptor through inhibition of cognate ligand binding. J. Immunol. 177, 7050\u20137058 (2006).","journal-title":"J. Immunol."},{"key":"63744_CR35","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1177\/1087057105274532","volume":"10","author":"SM Young","year":"2005","unstructured":"Young, S. M. et al. High-throughput screening with HyperCyt flow cytometry to detect small molecule formylpeptide receptor ligands. J. Biomol. Screen 10, 374\u2013382 (2005).","journal-title":"J. Biomol. Screen"},{"key":"63744_CR36","doi-asserted-by":"publisher","first-page":"4591","DOI":"10.4049\/jimmunol.150.10.4591","volume":"150","author":"K Wenzel-Seifert","year":"1993","unstructured":"Wenzel-Seifert, K. & Seifert, R. Cyclosporin H is a potent and selective formyl peptide receptor antagonist. Comparison with N-t-butoxycarbonyl-L-phenylalanyl-L-leucyl-L-phenylalanyl-L- leucyl-L-phenylalanine and cyclosporins A, B, C, D, and E. J. Immunol. 150, 4591\u20134599 (1993).","journal-title":"J. Immunol."},{"key":"63744_CR37","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.1016\/j.bmcl.2011.03.049","volume":"21","author":"J Unitt","year":"2011","unstructured":"Unitt, J. et al. Discovery of small molecule human FPR1 receptor antagonists. Bioorg. Med. Chem. Lett. 21, 2991\u20132997 (2011).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"63744_CR38","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1146\/annurev.immunol.18.1.309","volume":"18","author":"JD Ashwell","year":"2000","unstructured":"Ashwell, J. D., Lu, F. W. & Vacchio, M. S. Glucocorticoids in T cell development and function. Annu Rev. Immunol. 18, 309\u2013345 (2000).","journal-title":"Annu Rev. Immunol."},{"key":"63744_CR39","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1056\/NEJM197501302920504","volume":"292","author":"JJ Rinehart","year":"1975","unstructured":"Rinehart, J. J., Sagone, A. L., Balcerzak, S. P., Ackerman, G. A. & LoBuglio, A. F. Effects of corticosteroid therapy on human monocyte function. N. Engl. J. Med. 292, 236\u2013241 (1975).","journal-title":"N. Engl. J. Med."},{"key":"63744_CR40","doi-asserted-by":"publisher","first-page":"e12758","DOI":"10.1111\/dth.12758","volume":"32","author":"M Gilbert","year":"2019","unstructured":"Gilbert, M. & Scherrer, L. A. Efficacy and safety of cyclosporine in Stevens-Johnson syndrome and toxic epidermal necrolysis. Dermatol Ther. 32, e12758 (2019).","journal-title":"Dermatol Ther."},{"key":"63744_CR41","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.jaci.2010.10.030","volume":"127","author":"M Ballow","year":"2011","unstructured":"Ballow, M. The IgG molecule as a biological immune response modifier: mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorders. J. Allergy Clin. Immunol. 127, 315\u2013323 (2011).","journal-title":"J. Allergy Clin. Immunol."},{"key":"63744_CR42","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1001\/jamadermatol.2023.0035","volume":"159","author":"Y Miyamoto","year":"2023","unstructured":"Miyamoto, Y. et al. Evaluation of Plasmapheresis vs Immunoglobulin as first treatment after ineffective systemic corticosteroid therapy for patients with Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. JAMA Dermatol 159, 481\u2013487 (2023).","journal-title":"JAMA Dermatol"},{"key":"63744_CR43","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/S0140-6736(74)91415-9","volume":"2","author":"HY Mok","year":"1974","unstructured":"Mok, H. Y., Bell, G. D. & Dowling, R. H. Effect of different doses of chenodeoxycholic acid on bile-lipid composition and on frequency of side-effects in patients with gallstones. Lancet 2, 253\u2013257 (1974).","journal-title":"Lancet"},{"key":"63744_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/NEJM197201062860101","volume":"286","author":"RG Danzinger","year":"1972","unstructured":"Danzinger, R. G., Hofmann, A. F., Schoenfield, L. J. & Thistle, J. L. Dissolution of cholesterol gallstones by chenodeoxycholic acid. N. Engl. J. Med. 286, 1\u20138 (1972).","journal-title":"N. Engl. J. Med."},{"key":"63744_CR45","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/S0016-5085(19)33226-3","volume":"63","author":"H Greim","year":"1972","unstructured":"Greim, H. et al. Mechanism of cholestasis. 6. Bile acids in human livers with or without biliary obstruction. Gastroenterology 63, 846\u2013850 (1972).","journal-title":"Gastroenterology"},{"key":"63744_CR46","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1046\/j.1365-2362.1996.95240.x","volume":"26","author":"K Aouad","year":"1996","unstructured":"Aouad, K. et al. Immunosuppressive effects of endotoxins and bile acids in vivo in the rat. Eur. J. Clin. Invest 26, 45\u201348 (1996).","journal-title":"Eur. J. Clin. Invest"},{"key":"63744_CR47","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/0016-5085(80)90570-3","volume":"78","author":"L Gianni","year":"1980","unstructured":"Gianni, L., Di Padova, F., Zuin, M. & Podda, M. Bile acid-induced inhibition of the lymphoproliferative response to phytohemagglutinin and pokeweed mitogen: an in vitro study. Gastroenterology 78, 231\u2013235 (1980).","journal-title":"Gastroenterology"},{"key":"63744_CR48","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1002\/hep.1840100409","volume":"10","author":"JW Greve","year":"1989","unstructured":"Greve, J. W., Gouma, D. J. & Buurman, W. A. Bile acids inhibit endotoxin-induced release of tumor necrosis factor by monocytes: an in vitro study. Hepatology 10, 454\u2013458 (1989).","journal-title":"Hepatology"},{"key":"63744_CR49","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1002\/hep.1840160317","volume":"16","author":"Y Calmus","year":"1992","unstructured":"Calmus, Y. et al. Differential effects of chenodeoxycholic and ursodeoxycholic acids on interleukin 1, interleukin 6 and tumor necrosis factor-alpha production by monocytes. Hepatology 16, 719\u2013723 (1992).","journal-title":"Hepatology"},{"key":"63744_CR50","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1111\/j.0022-202X.2004.23439.x","volume":"123","author":"A Nassif","year":"2004","unstructured":"Nassif, A. et al. Evaluation of the potential role of cytokines in toxic epidermal necrolysis. J. Invest. Dermatol 123, 850\u2013855 (2004).","journal-title":"J. Invest. Dermatol"},{"key":"63744_CR51","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1001\/archderm.1994.01690050073012","volume":"130","author":"P Paquet","year":"1994","unstructured":"Paquet, P., Nikkels, A., Arrese, J. E., Vanderkelen, A. & Pi\u00e9rard, G. E. Macrophages and tumor necrosis factor alpha in toxic epidermal necrolysis. Arch. Dermatol. 130, 605\u2013608 (1994).","journal-title":"Arch. Dermatol."},{"key":"63744_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-52990-3","volume":"15","author":"A Gibson","year":"2024","unstructured":"Gibson, A. et al. Multiomic single-cell sequencing defines tissue-specific responses in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat. Commun. 15, 8722 (2024).","journal-title":"Nat. Commun."},{"key":"63744_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-54180-7","volume":"15","author":"CB Chen","year":"2024","unstructured":"Chen, C. B. et al. Immune checkpoint inhibitor-induced severe epidermal necrolysis mediated by macrophage-derived CXCL10 and abated by TNF blockade. Nat. Commun. 15, 10733 (2024).","journal-title":"Nat. Commun."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-63744-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-63744-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-63744-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T03:12:54Z","timestamp":1759633974000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-63744-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["63744"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-63744-0","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,30]]},"assertion":[{"value":"27 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T. N. is a current employee of POLA Chemical Industries, Inc. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8708"}}